Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 8-K (Current Report)
Date of Report: November 10, 2025
Reporting Period: Event-based report for November 10, 2025
BioCardia, Inc. is a Delaware corporation with principal executive offices in Sunnyvale, California. The company is listed on The Nasdaq Capital Market under the symbol BCDA. This filing reports a specific corporate event under Item 8.01 (Other Events).
Key Financial Metrics
This Form 8-K is an event-driven report and does not contain financial statements, revenue figures, profit data, cash flow information, margin analysis, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
The material change reported is a clinical trial milestone rather than a financial or operational restructuring. On November 10, 2025, the company announced the enrollment of the first patient at Henry Ford Health in its ongoing Phase 3 CardiAMP HF II clinical trial. This trial targets patients with ischemic heart failure of reduced ejection fraction.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the clinical milestone. No forward-looking financial guidance or updated operational outlook is provided within the text of this 8-K.
Risks and Contingencies: The filing includes a standard disclaimer stating that the information furnished in Item 8.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of such section. It is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed trial design and enrollment targets.
- Confirm the status of other sites in the Phase 3 CardiAMP HF II trial to assess overall enrollment velocity.
- Review recent 10-Q or 10-K filings for the most current financial position, cash runway, and burn rate, as this 8-K contains no financial data.
- Monitor subsequent 8-K filings for updates on patient enrollment milestones or potential trial delays.